Abstract
The objective of this work was to assess the efficacy of continuous proton pump inhibitor (PPI) therapy in children and to evaluate changes in biochemical, endoscopic, and histologic parameters during such treatment. A retrospective review of children receiving PPI therapy continuously for 1 year or more with baseline and follow-up esophageal and gastric biopsies on treatment was conducted to assess type, frequency, and duration of PPI dosing, symptom relief, gastrin levels, histologic findings, and adverse events. A total of 113 children (59 male, median age 4.5 years) were identified. Of these, 31% (35/113) were neurologically impaired. The median treatment duration was 35.2 months. Elevated serum gastrin levels occurred in 73% of children with no statistically significant differences in gastrin level by PPI type, dose, and dosing frequency or treatment duration. Adverse events were reported by 12% of children: diarrhea (5%) and constipation (4%) were the most frequent. Long-term PPI therapy appears to be effective, safe and well tolerated in children despite some biochemical, endoscopic, and histologic changes.
Similar content being viewed by others
References
Nelson SP, Chen EH, Syniar GM, Christoffel KK (1997) Prevalence of symptoms of gastroesophageal reflux during infancy. A pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 151:569–572
Nelson SP, Chen EH, Syniar GM, Christoffel KK (1998) One-year follow-up of symptoms of gastroesophageal reflux during infancy. Pediatrics 102(6):E67. http://www.pediatrics.org/cgi/content/full/102/6/c67
Nelson SP, Chen EH, Syniar GM, Christoffel KK, for the Pediatric Practice Research Group (2000) Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Arch Pediatr Adolesc Med 54:150–154
Ramesh P, Santiago M, Schmidt K, Gunasekaran TS (2001) Prevalence of gastroesophageal reflux disease symptoms in an African American predominant adolescent high school population. J Pediatr Gastroenterol Nutr 33:A194
Ramesh P, Braden D, Dey S, Gunasekaran TS (2002) Prevalence of gastroesophageal reflux disease (GERD) symptoms in a Caucasian predominant adolescent population. Gastroenterology 122:A213
Waring JP, Feiler MJ, Hunter JG, Smith CD, Gold BD (2002) Childhood gastroesophageal reflux symptoms in adult patients. J Pediatr Gastroenterol Nutr 35:334–338
El-Serag HB, Gilger M, Carter J, Genta RM, Rabeneck L (2004) Childhood GERD is a risk factor for GERD in adolescents and young adults. Am J Gastroenterol 100:806–812
DiBaise J, Young R, Ward B, Lyden E, Vanderhoof J (2005) A retrospective, case-control study of the natural history of pediatric GERD. Gastroenterology (4 Suppl 2):Abstract M1070
Hirschowitz BI, Simmons J, Mohnen J (2005) Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol 3(1):39–48
Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book L (2002) Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 35:S308–S318
Hassall E, Israel D, Shepherd R, Radke M, Dalvag A, Skold B, Junghard O, Lundborg P (2000) Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. J Pediatr 137:800–807
Huang J-Q, Hunt RH (1998) Meta-analysis of comparative trials for healing erosive esophagitis with proton pump inhibitors and H2-receptor antagonists. Gastroenterology 114:A154
Gunasekaran T, Gupta S, Gremse D, Karol M, Pan WJ, Chiu YL, Keith R, Fitzgerald J (2002) Lansoprazole in adolescents with gastroesophageal reflux disease. Pharmacokinetics, pharmcodynamics, symptom relief efficacy and tolerability. J Pediatr Gastroenterol Nutr 35(Suppl 4):S327–S335
Fiedorek S, Tolia V, Gold BD, Huang B, Stolle J, Lee C, Gremse D (2005) Efficacy and safety of lansoprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 40(3):319–327
Metz DC (2004) Managing gastroesophageal reflux disease for the lifetime of the patient: evaluating the long-term options. Am J Med 117(5A):49S–55S
Onimoe GI, Tolia V, Thomas R (2005) Clinical presentation and long term outcome of gastroesophageal reflux disease in children and adolescents. J Pediatr Gastroenterol Nutr 41(4):A34
Wang K, Lin HJ, Perng CL, Tseng GY, Yu KW, Chang FY, Lee SD (2004) The effect of H2-receptor antagonist and proton pump inhibitor on microbial proliferation in the stomach. Hepatogastroenterology 51(59):1540–1543
Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB (2004) Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292(16):1955–1960
Canani RB, Cirillo P, Roggero P et al. (2006) Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 117(5):e817–e820
Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, Lloyd D, Havu N, Frame MH, Roman J, Walan A (2000) Long-term study group long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology 118:661–669
Israel DM, Hassall E (1998) Omeprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children. J Pediatr Gastroenterol Nutr 27:568–579
Andersson T, Hassall E, Lundborg P, Shepherd R, Radke M, Marcon M, Dalvag A, Martin S, Behrens R, Koletzko S, Becker M, Drouin E, Gothberg G (2000) Pharmacokinetics of orally administered omeprazole in children: International Pediatric Omeprazole Pharmacokinetic Group. Am J Gastroenterol 95:3101–3106
Hassall E, El-Serag H, Kerr W (2005) Continuous use of proton pump inhibitors in children up to 11 yrs duration. Gastroenterology (4 Suppl 2): Abstract T1669
SAS Institute (2001) SAS 8.2. SAS Institute, Cary
Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, Mitchell B, Beveridge BR, Laurence BH, Gibson GG (1988) Healing and relapse of severe peptic oesophagitis after treatment with omeprazole. Gastroenterology 95(4):903–912
Dixon MF, Genta RM, Yardley JH, Correa P (1996) Classification and grading of gastritis. Am J Surg Pathol 20:1161–1181
Marchetti F, Gerarduzzi T, Ventura A (2003) Proton pump inhibitors in children: a review. Dig Liver Dis 35:738–746
Bohmer CJ, Niezen-de Boer RC, Klinkenberg-Knol EC, Meuwissen SG (1998) Omeprazole: therapy of choice in intellectually disabled children. Arch Pediatr Adolesc Med 152(11):1113–1118
DeVault KR, Castell DO (2005) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100(1):190–200
Pounder R, Smith J (1990) Drug-induced changes of plasma gastrin concentration. Gastroenterol Clin North Am 19:141–153
Mattsson H, Havu N, Brautigam J, Carlsson K, Lundell L, Carlsson E (1991) Parietal gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffin-like cell carcinoids in the rat. Gastroenterology 100:311–319
Freston JW, Borch K, Brand SJ, Carlsson E, Creutzfeldt W, Hakanson R, Olbe L, Solcia E, Walsh JH, Wolfe MM (1995) Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. A review and analysis. Dig Dis Sci 40(2 Suppl):50S–62S
Pashankar DS, Israel DM, Jevon GP, Buchan AM (2001) Effect of long-term omeprazole treatment on antral G and D cells in children. J Pediatr Gastroenterol Nutr 33(5):537–542
Singh P, Indaram A, Greenberg R, Visvalingam V, Bank S (2000) Long term omeprazole therapy for reflux esophagitis: follow-up in serum gastrin levels, EC cell hyperplasia and neoplasia. World J Gastrenterol 6:789–792
Hage E, Hendel L, Gustafsen J, Hendel J (2003) Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole. Eur J Gastroenterol Hepatol 15(7):781–789
Laine L, Ahnen D, McClain C, Solcia E, Walsh JH (2000) Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 14(6):651–668
Pashankar DS, Israel DM (2002) Gastric polyps and nodules in children receiving long-term omeprazole therapy. J Pediatr Gastroenterol Nutr 35(5):658–662
Graffner H, Singh G, Chaudry I, Milsom JW (1992) Omeprazole-induced hypergastrimenia does no influence growth of colon carcinoma. Dig Dis Sci 37(4):485–489
Pinson DM, Havu N, Sztern MI, Mattsson H, Looney GA, Kimler BF, Hurwitz A (1995) Drug-induced hypergastrinemia: absence of trophic effects on colonic carcinoma in rats. Gastroenterology 108(4):1068–1074
Litalien C, Theoret Y, Faure C (2005) Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 44(5):441–466
de Korwin JD, Ducrotte P, Vallot T (2004) New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases? Presse Med 33(11):746–754
Robinson M, Horn J (2003) Clinical pharmacology of proton pump inhibitors: what the practicing physician needs to know. Drugs 63(24):2739–2754
Ruscin JM, Page RL, Valuck RJ (2002) Vitamin B (12) deficiency associated with histamine (2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother 36(5):812–816
Valuck RJ, Ruscin JM (2004) A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 57(4):422–428
Howden CW (2000) Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 30(1):29–33
Force RW, Meeker AD, Cady PS, Culbertson VL, Force WS, Kelley CM (2003) Ambulatory care increased vitamin B12 requirement associated with chronic acid suppression therapy. Ann Pharmacother 37(4):490–493
ter Heide H, Hendriks HJ, Heijmans H, Menheere PP, Spaapen LJ, Bakker JA, Forget PP (2001) Are children with cystic fibrosis who are treated with a proton-pump inhibitor at risk for vitamin B(12) deficiency? J Pediatr Gastroenterol Nutr 33(3):342–345
Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24):2947–2953
Acknowledgements
The authors wish to thank Elizabeth Crane and Qin Qin for help with data analysis and Susan Ruffalo, of MedWrite, Newport Coast, CA, USA, for editorial assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
Presented in part at Digestive Disease Week 2005, Chicago, IL, USA.
Rights and permissions
About this article
Cite this article
Tolia, V., Boyer, K. Long-Term Proton Pump Inhibitor Use in Children: A Retrospective Review of Safety. Dig Dis Sci 53, 385–393 (2008). https://doi.org/10.1007/s10620-007-9880-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-007-9880-7